03:59 AM EDT, 08/19/2026 (MT Newswires) -- Initiator Pharma (INIT.ST) secured patents related to its female sexual dysfunction treatment, pudafensine, from the European Patent Office. The Danish clinical-stage pharmaceutical company said Wednesday that the two patents cover the therapy's use for pain alleviation and its oral formulation. The company noted that the pain treatment patent will be valid until 2043, while the formulation patent will be active until 2044.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.